comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-05 18:33:20 - browse：61613

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Philips to halt sales of sleep apnea machines in U.S.

knowledge

WSS

Why Charlie Gard's case is so disturbing to Americans

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The Affordable Care Act has saved billions in health care costs

Senate panel eyes new effort on drug shortages

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Health Care Service Corp to buy Cigna Medicare Advantage plans

explore

comprehensive

knowledge

Cancer drug shortages should be causing more outrage

Why Charlie Gard's case is so disturbing to Americans

What does generative AI mean for health care? We asked experts

Investment in vaccine development is lagging, report finds

New air purifier tech could be key to improving indoor air quality

New clues to why women have higher risk of autoimmune disorders

Guidelines to prevent youth baseball injuries need more muscle

Investment in vaccine development is lagging, report finds

Cancer drug shortages should be causing more outrage

A virus, fished out of a lake, may have saved a man’s life

hotspot

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Syphilis numbers in the United States reach record heights

AI can decode, harness the power of the humane immune system

Stroke deaths set to near 10 million globally by 2050

A virus, fished out of a lake, may have saved a man’s life

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

entertainment

explore

knowledge

entertainment